NCT01475695View on ClinicalTrials.gov

GSK2251052 Mass Balance in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

April 21, 2011

Primary Completion Date

May 19, 2011

Study Completion Date

May 19, 2011

Conditions

Community-acquired Infection

Interventions

DRUG

14C GSK2251052

1500 mg iv dose GSK2251052

Trial Locations (1)

9471 GP

GSK Investigational Site, Zuidlaren

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01475695 - GSK2251052 Mass Balance in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter